December 21, 2017 / 8:10 AM / 9 months ago

BRIEF-vTv Therapeutics Signs Agreement With Hangzhou Zhongmei For Rights of Glp-1R Agonist Diabetes Program

Dec 21 (Reuters) - vTv Therapeutics Inc:

* VTV THERAPEUTICS INC SAYS LICENSING AGREEMENT WITH HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO. TO RIGHTS FOR VTV’S GLP-1R AGONIST DIABETES PROGRAM

* VTV THERAPEUTICS-GRANTED HUADONG PHARMACEUTICAL EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE GLP-1R AGONIST PROGRAM IN CHINA, HK, AND OTHER COUNTRIES

* VTV THERAPEUTICS INC SAYS WILL RECEIVE AN $8 MILLION UPFRONT PAYMENT AND IS ELIGIBLE FOR UP TO AN ADDITIONAL $75 MILLION IN MILESTONE PAYMENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below